Bizily Scott 4

4 · 4D Molecular Therapeutics, Inc. · Filed Jun 25, 2026

AI-generated summary of this filing

Updated Jun 25, 2026

4D Molecular Therapeutics (FDMT) CLO Scott Bizily Exercises Options, Sells Shares

What Happened

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics (FDMT), exercised stock options to acquire 9,810 shares at $4.14 per share (cost $40,613) and then sold those 9,810 shares in the open market at $12.00 per share for total proceeds of $117,720 on June 23, 2026. The filing also reports a derivative disposition at $0 associated with the option conversion/exercise.

Key Details

Transaction date: June 23, 2026 (Form 4 filed June 25, 2026)
Exercise (Code M): 9,810 shares acquired at $4.14 each — $40,613 total cost
Sale (Code S): 9,810 shares sold at $12.00 each — $117,720 total proceeds
Derivative line: 9,810 shares disposed at $0, reflecting conversion/exercise of the option
Shares owned after transaction: Not disclosed in this filing
Footnotes:
- F1: Reflects 5,023 shares purchased under the company Employee Stock Purchase Plan (Rule 16b-3 exemption).
- F2: The option subject to exercise vests monthly (1/48 per month) beginning March 6, 2025; fully vested after four years if service continues.
Filing timeliness: Reported on the SEC on June 25, 2026 (two days after the trade date).

Context

This was an option exercise followed by an immediate sale of the exercised shares (a cashless-style outcome). Such transactions commonly occur for liquidity or tax-payment reasons and are not, by themselves, a clear signal of the insider’s view on the company.
Transaction codes: M = exercise/conversion of derivative; S = sale in open market.

Form 4

Period: 2026-06-23

Chief Legal Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-06-23$4.14/sh+9,810$40,613→ 18,427 total
Sale
Common Stock
2026-06-23$12.00/sh−9,810$117,720→ 8,617 total
Exercise/Conversion
Stock Option (Right to Buy)
[F2]
2026-06-23−9,810→ 63,785 total
Exercise: $4.14Exp: 2035-03-05→ Common Stock (9,810 underlying)

Footnotes (2)

[F1]Reflects 5,023 shares of the Issuer's common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.
[F2]The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Signature

/s/ Scott Bizily|2026-06-25

1 file